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Background: Blood-borne biomarkers for early detection of colorectal cancer (CRC) could markedly increase screening uptake.
The aim of this study was to evaluate serum carcinoembryonic antigen (CEA), CYFRA21-1 and CA125 for the early detection of
CRC in an asymptomatic cohort.
Methods: This nested case–control study within UKCTOCS used 381 serial serum samples from 40 women subsequently
diagnosed with CRC, 20 women subsequently diagnosed with benign disease and 40 matched non-cancer controls with three to
four samples per subject taken annually up to 4 years before diagnosis. CEA, CYFRA21-1 and CA125 were measured using
validated assays and performance of markers evaluated for different pre-diagnosis time groups.
Results: CEA levels increased towards diagnosis in a third of all cases (half of late-stage cases), whereas longitudinal profiles were
static in both benign and non-cancer controls. At a threshold of45 ngml 1 the sensitivities for detecting CRC up to 1 and 4 years
before clinical presentation were 25% and 13%, respectively, at 95% specificity. At a threshold of42.5 ngml 1, sensitivities were
57.5% and 38.4%, respectively, with specificities of 81% and 83.5%. CYFRA21-1 and CA125 had no utility as screening markers and
did not enhance CEA performance when used in combination. CEA gave average lead times of 17–24 months for test-positive
cases.
Conclusions: CEA is elevated in a significant proportion of individuals with preclinical CRC, but would not be useful alone as a
screening tool. This work sets a baseline from which to develop panels of biomarkers which combine CEA for improved early
detection of CRC.
Colorectal cancer (CRC) is a major burden worldwide. In the
United Kingdom alone, there were 40 695 new cases and 15 708
mortalities in 2010 (CRUK, 2014). Development of a colorectal
tumour to the point of metastasis, often incurable, is a lengthy
period that proceeds through a pre-malignant stage, where simple
polypectomy is curative, and an early, localised malignant stage
that is treatable. Survival rates are more favourable when detected
earlier; 93, 77, 48 and 7% of those diagnosed at stages I to IV,
respectively, survive 5 years (NCIN, 2010). Early detection of CRC
is therefore crucial to reducing mortality from the disease.
Advanced polyps and cancers bleed intermittently and the faecal
occult blood test (FOBT) is used to detect trace amounts of
haemoglobin in stool samples. Biennial FOBT-based screening,
which was implemented in the National Health Service (NHS)
Bowel Cancer Screening Programme (NHSBCSP) in the United
Kingdom, is associated with a 15% reduction in mortality and a
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stage shift towards earlier detection (Hewitson et al, 2007; Gill et al,
2012; Logan et al, 2012). Other trials have reported mortality
reductions of 15%–33% using FOBT-based screening (Mandel
et al, 1993; Selby et al, 1993; Hardcastle et al, 1996; Kronborg et al,
1996; Lindholm et al, 2008). The potential benefits are compro-
mised by the limited sensitivity (13–50%) of the FOBT for
detection in asymptomatic cohorts (Allison et al, 1990; Imperiale
et al, 2004) and poor uptake (52%) since implementation (Logan
et al, 2012). Flexible sigmoidoscopy is the other first line screening
test (followed by colonoscopy if positive) that affords greater
sensitivity over FOBT, detecting 70–80% of advanced neoplasms of
the colorectum (Whitlock et al, 2008). It has proven to be
efficacious for screening (Atkin et al, 2010; Holme et al, 2013;
Schoen et al, 2012), although cannot be used to detect theB40% of
tumours that develop in the proximal colon (Whitlock et al, 2008).
Screening with gold-standard diagnostic colonoscopy is advocated
for high-risk groups in the United Kingdom (Cairns et al, 2010)
and sporadic cancer in the United States (Levin et al, 2008).
However, compliance rates for these invasive tests are low (Robb
et al, 2010; Taylor et al, 2011).
Blood tests are routinely used for biomarker determination and
are widely accepted, and it is reasoned that the transition to an
initial blood tumour marker test for CRC screening would improve
uptake due its less invasive nature than either FOBT or flexible
sigmoidoscopy. However, no serum tumour markers have
approved screening utility for CRC (Locker et al, 2006; Duffy
et al, 2014), and although a recently evaluated plasma septin 9
(SEPT9) DNA methylation test (Epi proColon) holds some
promise (Church et al, 2013; Johnson et al, 2014), increased
uptake (vs faecal testing) in non-compliant populations needs to be
demonstrated. Poor clinical translation may be, in part, due to the
lack of established biorepositories with extended patient follow-up
that can yield preclinical samples drawn from asymptomatic
individuals who eventually developed cancer. Biomarker testing in
such samples is likely to improve validity and confidence in
identifying markers with screening utility in the absence of clinical
stage confounders (Pepe et al, 2008; Buchen, 2011).
Carcinoembryonic antigen (CEA) is the most routinely used
colorectal tumour marker, and is recommended by the National
Academy of Clinical Biochemistry and American Society of
Clinical Oncology for prognosis, monitoring response to treatment
and for detecting metastatic disease and disease recurrence (Locker
et al, 2006; Duffy et al, 2014). However, serum CEA has limited
sensitivity for screening in asymptomatic people. CEA testing on
46 preclinical cases (29 early stage/17 advanced stage) provided a
lead time of up to 2 years in 30% of future CRCs at a cutoff
threshold that correctly identified 99% of controls (Palmqvist et al,
2003). In another study, elevated CEA conferred a lead time of up
to 7 months in 19% of 32 (17 early stage/15 advanced stage)
preclinical cases (Ladd et al, 2012). Both studies, however, involved
the use of a single cross-sectional sample and were limited to a
maximum of a 2-year lead time. The circulating cytokeratin 19
fragment, CYFRA21-1, has been demonstrated as a useful
biomarker in several malignancies, notably lung, urinary bladder
and head and neck cancers (Barak et al, 2004). The diagnostic
performance of CYFRA21-1 for CRC has been assessed in two
studies (Wild et al, 2010; Lee, 2013), although its potential for
screening using preclinical samples has not been evaluated.
Herein, we present a nested case–control study within the UK
Collaborative Trial for Ovarian Cancer Screening (UKCTOCS); a
multi-centre randomised controlled trial that aims to inform on
the viability of an ovarian cancer screening programme in the
United Kingdom (Menon et al, 2008, 2009). The UKCTOCS
biorepository includes samples from 50 640 women randomised to
the multi-modal arm, who donated serum annually for up to 11
years for ovarian cancer screening using cancer antigen 125
(CA125) levels. The present study aims to evaluate the
performance of CEA, CYFRA21-1 and CA125 for the early
detection of CRC in an asymptomatic cohort by profiling tumour
marker levels in four annual longitudinal serum samples collected
from women who subsequently developed CRC, benign neoplasms
of the colorectum or remained cancer free. We also wanted to
address the reported link between smoking and raised serum CEA
levels (Alexander et al, 1976; Chevinsky, 1991).
MATERIALS AND METHODS
Ethical approval. The present study was approved by the NHS
National Research Ethics Service (REC 13/EM/0191). UKCTOCS
participants gave informed written consent at recruitment for the
use of their medical notes and serum in secondary and/or
commercial studies. Ethical approval for UKCTOCS was granted
by the UK North West Medical Research and Ethics Committee
(MREC 00/8/34).
Case identification, confirmation and characterisation. UKC-
TOCS participants were post-menopausal women aged 50–74, who
had no active malignancy at recruitment (Menon et al, 2008).
Notifications of women subsequently diagnosed with CRC were
retrieved by querying the Health and Social Care Information
Centre cancer and death registries and Hospital Episode Statistics
(HES) data with the International Classification of Diseases (ICD-
10) codes pertaining to malignant neoplasms of the colon (C18,
excluding appendix (C18.1)), the rectosigmoid junction (C19) and
rectum (C20). Cancer notifications were also received via self-
reported data completed 3.5 years post randomisation to the
UKCTOCS. CRC notifications were confirmed and characterised
by postal questionnaire sent to treating clinicians (consultant, or
General Practitioner if details not provided by the volunteer),
which was designed to ascertain clinical and histological data on
diagnosed cases (date of diagnosis, primary site, stage, grade,
morphology and treatment). Benign neoplasms of the colon and
rectum (D12), excluding those of the appendix (D12.1), anus and
anal canal (D12.9) were identified through HES (England only).
Study set. The study set consisted of longitudinal preclinical
samples collected 0–4 years before the eventual diagnosis of
colorectal adenocarcinoma in 40 women (20 early stage, defined as
Dukes’ A/B and 20 late stage, defined as Dukes’ C/D), or benign
neoplasms of the colon and rectum in 20 women, and matched
samples from 40 control women; 20 matched to the early stage and
20 matched to the late-stage adenocarcinoma cases; see
Supplementary Data, Supplementary Table S1 for clinical and
histological data, Supplementary Table S2 for the number of
samples associated with each time and clinical group). Benign cases
did not develop any type of malignancy during the study period
and had no previous diagnoses of any type of malignancy
according to HES records. Likewise, non-cancer controls did not
develop, and had no previous record of any type of malignancy
according to the cancer registry, HES, UKCTOCS or self-reported
data, or any diagnosis of a benign neoplasm of the colorectum
according to HES. Benign cases were matched 1:1 with early-stage
adenocarcinoma cases by age at sample donation (±5 years) and
collection centre (same, excluding six cases in trial centres in
Northern Ireland and Wales, which were matched to the nearest
trial centre in England). Non-cancer controls were individually
matched 1:1 to early and late-stage cases by trial centre, age at final
sample draw (±5 years) and date of sample draw (same day for
0–1 year preclinical sample and ±4 months for 3–4 years
preclinical sample). Baseline characteristics, ethnicity, current
hormone replacement therapy (HRT) use, oral contraceptive pill
(OCP) use, OCP use duration, ever smokers, age at randomisation,
body mass index (BMI) and age at last period were taken from the
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UKCTOCS recruitment questionnaire (Fourkala et al, 2014) and
are shown for all study subjects in Table 1.
Serum marker determinations. Blood was collected and serum
prepared according to a standardised protocol within UKCTOCS
(Menon et al, 2009) and then shipped frozen to a cryo-repository
for long-term storage in liquid nitrogen. For the study, samples
were retrieved and shipped to the laboratory on dry ice and thawed
at 4 1C for aliquoting before carrying out assays. Serum CEA and
CYFRA21-1 levels were determined using the Cobas immuno-
assays and platform (Roche Diagnostics, Burgess Hill, UK) with
relevant calibrator set and PreciControl tumour marker standards
for quality control (Roche Diagnostics). All marker determinations
were carried out by a single experienced researcher (RG) who was
blinded to all information regarding the sample and UKCTOCS
volunteer. The present study made use of CA125 levels determined
previously for the UKCTOCS.
RESULTS
Study set characteristics. The study set comprised of 381
longitudinal serum samples from 100 women for CEA and
CYFRA21-1 testing and 456 CA125 measurements from the same
women (Supplementary Data, Supplementary Table S2). These
samples were drawn from groups of 20 early- and late-stage CRC
cases and matched benign and non-cancer controls. There was no
significant difference between these groups in terms of their
ethnicity, the number of current HRT and OCP users, ever
smokers, OCP use duration, age at randomisation, BMI and age at
last period (Table 1). Furthermore, there was no significant
difference between the groups in terms of the time from sample
draw to centrifugation (data not shown) with a median time to
spin of 21.7 h (IQR 20.0–23.6 h). Thus, differences in time to spin
could not account for any differences in serum analyte levels
between groups.
Longitudinal profiles. The longitudinal behaviour of serum CEA,
CYFRA21-1 and CA125 in the lead up to cancer and benign
neoplasm diagnosis and in matched non-cancer controls was
assessed. Graphical representations of these determinations
stratified according to clinical group and time to diagnosis group
are shown in Figure 1 with median values for groups presented in
Table 2. Elevated levels of CEA in cases (all stages) compared with
non-cancer controls were significant up to 2 years before diagnosis
(Po0.05) and could also discriminate cancers from benign
neoplasms (data not shown). Notably, CEA levels in early-stage
cases were significantly elevated 42 years compared with late-
stage cases (Po0.05). This difference could be visualised with a
linear regression model (Figure 2). Examination of individual
longitudinal profiles (Supplementary Data, Supplementary Figure
S1) showed CEA levels to be rising towards diagnosis only in
cancer cases and to be relatively static in benign and non-cancer
controls at each annual blood draw. Elevation of CEA towards
diagnosis was apparent in 3/20 early-stage and 10/20 late-stage
cancer cases. Several subjects (three CRC, one benign and three
non-cancer controls) had high CEA levels (44 ngml 1) that were
static across the time course.
CYFRA21-1 levels were not significantly different (P40.05)
between cases and controls for any of the time groups examined
(Table 2) and only weak and non-significant correlations were
observed between CYFRA21-1 levels and time to diagnosis
(R2¼ 0.115 for early stage; R2¼ 0.094 for late stage). CYFRA21-1
levels rose towards diagnosis in 17 of the 40 (42.5%) CRC cases,
but also in 17 of the 60 (28.3%) benign and non-cancer controls,
although levels were rarely above the clinical threshold of
3.3 ngml 1 (Molina et al, 1994; Rastel et al, 1994; data not
shown). Changing CYFRA21-1 levels were not attributable to time
in storage or time to spin. CA125 levels did not differ significantly
between cases and controls for any of the time groups, although
levels were significantly higher in the late stage vs early-stage case
samples taken 2–3 and 3–4 years before diagnosis.
Biomarker performance. CEA and CYFRA21-1 were assessed
individually and in combination for their ability to discriminate all
cases from benign and non-cancer controls using different cutoff
values (Supplementary Data, Supplementary Table S3A). CA125
was not examined in combination. At the commonly used
threshold of 45 ngml 1, CEA had a sensitivity and specificity
of 25% and 95% at 0–1 years, 14% and 92% at 1–2 years, 11% and
98% at 2–3 years, 3% and 93% at 3–4 years and 13% and 94% 0–4
years to diagnosis. Specificity values changed little when only the
cases of benign neoplasms were considered (Supplementary Table S3B).
Table 1. Baseline characteristics of study set
Baseline characteristic
Control (matched to
early-stage case),
n¼20
Early-stage case
(Duke’s A/B),
n¼20
Benign,
n¼20
Control (matched
to late-stage case),
n¼20
Late-stage case
(Duke’s C/D),
n¼20 P-value
Number (%) v2-test
Ethnicity (n) 0.978
White 19 (95%) 19 (95%) 18 (90%) 20 (100%) 19 (95%)
Black 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Other 1 (5%) 1 (5%) 2 (10%) 0 (0%) 1 (5%)
Current HRT users (n) 4 (20%) 5 (25%) 5 (5%) 3 (15%) 3 (15%) 0.87
Ever OCP users (n) 7 (35%) 10 (50%) 12 (60%) 10 (50%) 6 (30%) 0.303
Ever smokers (n) 7 (35%) 7 (35%) 8 (40%) 5 (25%) 2 (10%) 0.161
Mean (s.d.) ANOVA
Age at randomisation (years) 61.3 (5.2) 62.1 (5.5) 61.5 (6.1) 62.5 (6.0) 62.7 (6.0) 0.913
BMI (kgm 2) 26.0 (4.2) 25.8 (5.3) 27.4 (5.4) 26.6 (5.1) 25.3 (3.5) 0.667
Age at last period (years) 49.9 (7.5) 49.5 (4.9) 47.7 (6.3) 49.9 (5.3) 49.5 (4.7) 0.742
Median (IQR) Kruskal–Wallis
OCP duration in users (years) 10.0 (4) 3.0 (11.8) 5.5 (8.0) 5.0 (6.0) 5.5 (16.6) 0.307
Abbreviations: ANOVA¼ analysis of variance; BMI¼body mass index; HRT¼ hormone replacement therapy; IQR¼ interquartile range; OCP¼oral contraceptive pill. Early case refers to Dukes’
stages A and B colorectal adenocarcinomas. Late case refers to Dukes’ stages C and D colorectal adenocarcinomas. Early and late controls are the corresponding matched non-cancer controls.
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At a lower cutoff value of 2.5 ngml 1, the sensitivity and
specificity were 57.5% and 81% at 0–1 years, 37.8% and 87.9% at
1–2 years, 30.6% and 83.6% at 2–3 years, 26.3% and 88.3% at 3–4
years and 38.4% and 83.5% 0–4 years (Supplementary Table S3A).
CYFRA21-1 at a cutoff threshold of 3.3 ngml 1 had encouraging
specificities (all 496%), but only detected 4 and 1 out of the 40
cases in the 0–1 and 1–2 year time groups, respectively, and
detected no preclinical benign neoplasms. At a 2 ngml 1 thresh-
old, the sensitivity for CYFRA21-1 was 14.6% at a specificity of
90% when all samples were considered. Simple combination ‘OR’
models showed some improvement in sensitivity, but at significant
cost to specificity (Supplementary Table S3). ROC curve analysis
confirmed that CEA was able to differentiate all cases from
controls up to 2 years before diagnosis, with superior and
significant areas under the curve demonstrated for early vs late-
stage cases beyond 2 years (Table 2). The poor performance of
CYFRA21-1 as an early biomarker of CRC was further highlighted
by insignificant areas under the curve. Neither CEA nor
CYFRA21-1 could significantly discriminate benign cases from
non-cancer controls.
Lead time estimates were calculated by averaging the earliest
time point of detection for CEA test-positive cases at the 5 and
2.5 ngml 1 thresholds. Mean lead time was 16.9 months (median
17.9 months; IQR 4.9–26.3) using 45 ngml 1 and 24.1 months
(median 23.0 months; IQR 7.3–39.9) using 42.5 ngml 1. By
comparison, linear regression models (Figure 2) estimated a lead
time of 12.8 and 15.8 months at 45 ngml 1 for detecting early-
and late-stage cancers, respectively, whereas at 42.5 ngml 1, the
lead time was 36.2 and 28.6 months, respectively.
Smoking and CEA levels. To address the link between smoking
and raised CEA levels, we combined smoking data (ever/never)
provided by UKCTOCS women at 3.5 years post randomisation
and CEA levels determined at 3-4 years pre-diagnosis for 78 of the
100 study subjects. Using this subset of data, there was a significant
positive association between elevated CEA (45 ngml 1) and ever
smoking (P¼ 0.042), although this significance was lost when the
lower threshold (42.5 ngml 1) was used. Using the whole data
set (304 CEA data points from 80 respondents), the association
between smoking and CEA level was significant at both thresholds
(45 ngml 1, P¼ 0.031 and 42.5 ngml 1, P¼ 0.0047). Further-
more, of the three out of the seven subjects with consistently
elevated CEA who had responded about smoking, all three were
ever smokers.
DISCUSSION
To our knowledge, this is the first study to examine the serum
levels of CEA, CYFRA21-1 and CA125 in longitudinal samples
taken before the diagnosis of CRC. CEA level increased towards
diagnosis in 32.5% of all cases and was raised above 2.5 ngml 1
3–4 years before diagnosis in 26.3% of cases. Longitudinal CEA
levels did not change significantly over time in any of the benign
cases or non-cancer controls. This suggests that only a subset of
colorectal adenocarcinomas produce an elevation in serum
CEA, and that this is specific to the malignant phenotype
(Hammarstrom, 1999). Rising CEA towards diagnosis was more
frequent in late-stage tumours, as reported previously (Wanebo
et al, 1978), but did not correlate with grade (data not shown), as
suggested previously (Goslin et al, 1981). Although we confirmed
that ever smokers were significantly more likely to have elevated
CEA levels, only two cases with rising CEA profiles were ever
smokers. Indeed, ever smokers tended to have elevated, but static
longitudinal CEA profiles, and occurred equally in both cases and
controls with only a small impact on specificity.
Using a threshold of45 ngml 1, CEA had a sensitivity of 25%
at 95% specificity up to 1 year before clinical diagnosis, and 13%
sensitivity up to 4 years. In a screening programme, this would
result in one in four cancers being detected up to 1 year before
clinical presentation and 5 out of 100 ‘healthy’ attendants being
referred for colonoscopy unnecessarily. Lowering the threshold to
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Figure 1. Serum measurements. Serum measurements for (A) CEA,
(B) CYFRA21-1 and (C) CA125. Box and whiskers denote the 25th/50th/75th
percentiles and minimum and maximum values, respectively.
Early case refers to Dukes’ stages A and B colorectal adenocarcinomas.
Late case refers to Dukes’ stages C and D colorectal adenocarcinomas.
Early and late controls are the corresponding matched non-cancer
controls. Date of diagnosis for controls corresponds with that of their
matched case.
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2.5 ngml 1 would result in 32.5% additional cancers being
detected up to 1 year before clinical presentation (25.4% up to 4
years), but may cause an unacceptably high proportion (14%) of
false-positives (10.5% for up to 4 years) requiring unnecessary
colonoscopy investigations. These findings are in line with other
studies examining CEA in cross-sectional pre-diagnosis samples
(Palmqvist et al, 2003; Ladd et al, 2012), and we conclude therefore
that on its own, serum CEA would have little use in screening
asymptomatic, average risk populations. Despite this, we report
respectable lead times in women with elevated CEA, indicating its
potential as a first line test for early detection, particularly if it were
to be combined with other markers, or used in a longitudinal
algorithm, to increase performance. Although CEA may be
superior to the guaiac FOBT (Allison et al, 1990, 1996;
Ransohoff and Lang, 1997; Imperiale et al, 2004), it appears
inferior to Cologuard (a faecal test combining haemoglobin
protein, NDRG4 and BMP3 gene promoter hypermethylation,
seven KRAS gene point mutations and b-actin DNA as a
normalisation marker), the faecal immunochemical test (a more
precise version of the FOBT for detecting haemoglobin) and Epi
proColon (plasma SEPT9 DNA methylation), which have been
evaluated in large prospective trials (Guittet et al, 2007; Church
et al, 2013; Raginel et al, 2013; Johnson et al, 2014; Lee et al, 2014;
Imperiale et al, 2014a,b). However, we highlight the fact that the
faecal-based tests have relatively poor acceptance to the general
population compared with blood-based tests due to a general
aversion to faecal sampling. Importantly, the performance of these
tests far in advance of diagnosis, and the lead time benefits
afforded, have yet to be determined. Thus, CEA may still have
some utility for the earlier detection of CRC if used in combination
with a more sensitive marker. Such markers should complement
CEA, detecting those cancers that were not positive for CEA, with
TIMP1, VEGF, sCD26 and PKM2 showing some promise.
Despite numerous reports of CYFRA21-1 as a specific marker of
multiple malignancies and our evidence of its elevation towards
diagnosis in some cases, its performance as a screening marker was
Table 2. Serum CEA and CYFRA21-1 by time to diagnosis group and clinical group
Years to diagnosis CEA CYFRA21-1
Group
Mean
(years)
Median
(ngml1)
P-value vs
Ctrl AUC
P-value
AUC
Median
(ngml1)
P-value vs
Ctrl AUC
P-value
AUC
All stages
0–1 0.48 2.7 0.0002 0.74 o0.001 1.47 NS 0.6 NS
1–2 1.49 2.03 0.042 0.64 0.042 1.18 NS 0.51 NS
2–3 2.46 1.83 NS 0.61 NS 1.15 NS 0.58 NS
3–4 3.48 1.66 NS 0.59 NS 1.13 NS 0.52 NS
Early stage
0–1 0.48 2.61 0.012 0.73 0.011 1.47 NS 0.66 NS
1–2 1.55 2.51 0.037 0.7 0.036 1.42 NS 0.67 NS
2–3 2.48 2.4 0.024 0.71 0.023 1.15 NS 0.53 NS
3–4 3.57 2.27 0.008 0.76 0.007 1.28 NS 0.64 NS
Late stage
0–1 0.48 2.81 0.008 0.75 0.007 1.54 NS 0.56 NS
1–2 1.44 1.65 NS 0.59 NS 1.14 NS 0.65 NS
2–3 2.43 1.26 NS 0.51 NS 1.11 NS 0.67 NS
3–4 3.4 1.17 NS 0.51 NS 1.04 NS 0.6 NS
Benign
0–1 0.59 1.25 NS 0.58 NS 1.17 NS 0.54 NS
1–2 1.58 1.55 NS 0.54 NS 1.03 NS 0.54 NS
2–-3 2.49 1.72 NS 0.5 NS 0.99 NS 0.66 NS
3–4 3.53 1.52 NS 0.54 NS 0.96 NS 0.51 NS
Control early
0–1 0.48 1.67 — — — 1.18 — — —
1–2 1.44 1.61 — — — 1.07 — — —
2–3 2.43 1.39 — — — 1.2 — — —
3–4 3.4 1.4 — — — 0.93 — — —
Control late
0–1 0.48 1.62 — — — 1.49 — — —
1–2 1.44 1.37 — — — 1.31 — — —
2–3 2.43 1.58 — — — 1.37 — — —
3–4 3.4 1.53 — — — 1.17 — — —
Abbreviations: AUC¼ area under the curve; CEA¼ carcinoembryonic antigen; Ctrl¼ control; NS¼ non-significant. Median values and P-values (vs controls) and areas under the ROC curve
(AUC) and associated P-value are given for each group and comparison. Refer to Supplementary Table S2 for sample numbers in each group.
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Figure 2. Linear regression longitudinal CEA profiles in cases and
controls. The linear regression models with R2¼0.072 and R2¼0.133
for early- and late-stage cases, respectively, significantly deviated from
zero (Po0.05). A CEA threshold of 45 ngml1 gave a lead time
benefit of 1.07 and 1.32 years for detection of early- and late-stage
cancers, respectively. At a threshold of42.5 ngml1, lead times were
3.02 and 2.38 years, respectively.
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very poor and it did not add to CEA when used in combination.
We conclude that serum CYFRA21-1 cannot be used as an early
marker of CRC and would have limited diagnostic use. Similarly,
and perhaps as expected, CA125 also proved to be a poor
biomarker of preclinical CRC.
Our study has several limitations. First, only post-menopausal
women were studied, and although this reflects the timing of
diagnosis of most CRCs it may not reflect the utility of CEA as a
colorectal tumour marker in the overall population. Given that
incidence rates are around 1.7 times higher in males vs females in
this age group, then 63% of the population would not be
represented. Second, only relatively small numbers of cases and
controls were examined, although they were carefully matched and
with longitudinal samples selected up to 4 years prior to diagnosis.
Third, the smoking status of our study cohort was not complete
and was restricted to dichotomous data (ever/never), limiting our
evaluation of its impact on test performance. However, the key
strength of the study is that highly characterised preclinical,
longitudinal samples were investigated, allowing an objective
assessment of how serological markers change during disease
progression. We conclude that in line with previous studies, CEA
alone cannot be used for CRC screening in asymptomatic
populations. Despite this, our work lays the groundwork for
building and assessing longitudinal algorithms for CRC screening
and combining promising new candidate biomarkers with CEA to
improve performance.
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